Med-IQ Logo
Get CME/CE
When Antidepressants Aren’t Enough to Control MDD: The Role of Augmentation With Second-Generation Antipsychotics
E-Publication E-Publication

When Antidepressants Aren’t Enough to Control MDD: The Role of Augmentation With Second-Generation Antipsychotics


Time to Complete:
30 minutes
Released:
7/31/17
Expires:
7/30/18

Maximum Credits:

0.5 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
30 minutes

Released:
7/31/17

Expires:
7/30/18

Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
Share on:
E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
30 minutes
Released:
7/31/17
Expires:
7/30/18


Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)


Overview: This online publication discusses practical challenges related to the management of patients with major depressive disorder whose symptoms do not resolve with antidepressant therapy and explores the role of second-generation antipsychotics (SGAs) in treatment augmentation plans for these patients. The efficacy and safety of SGAs as adjuncts to antidepressant therapy and differences among available SGAs are also discussed.

Faculty

Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences

New York Medical College

Valhalla, NY

Michael Thase, MD

Professor of Psychiatry

University of Pennsylvania School of Medicine

Pittsburgh, PA


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Leslie Citrome, MD, MPH
Consulting fees/advisory boards: ACADIA Pharmaceuticals Inc., Alkermes, Allergan, Inc., FORUM Pharmaceuticals Inc., Intra-Cellular Therapies, Janssen Pharmaceuticals, Inc., Lundbeck, Merck & Co., Inc., Neurocrine Biosciences, Noven Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals North America, Inc., Teva Neuroscience, Inc., Vanda Pharmaceuticals, Inc.
Fees received for promotional/non-CME activities: ACADIA Pharmaceuticals Inc., Alkermes, Allergan, Inc., Janssen Pharmaceuticals, Inc., Lundbeck, Merck & Co., Inc., Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals North America, Inc., Vanda Pharmaceuticals, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc.
 
Michael Thase, MD
Consulting fees/advisory boards: ACADIA Pharmaceuticals Inc., Alkermes, Allergan, Inc., AstraZeneca, Cerecor, Inc., Eli Lilly & Company, Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Lundbeck, MedAvante, Inc., Merck & Co., Inc., Moksha8, Nestle Health Science – Pamlab, Inc., Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire, Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals North America, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): MedAvante, Inc.

The writer, peer reviewers, and other activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
Play Video
The trifecta of healthcare improvement: value-based care, quality improvement, and technology.

See how Med-IQ is helping to enhance patient outcomes in these short videos.

Scott Weber, CEO Med-IQ

From Volume to Value-Based Care: The Role of the CME Enterprise

Scott Weber, CEO,
Med-IQ

Allison Gardner, PhD, VP Educational Strategy and Content, Med-IQ

The Value of Quality Improvement and Education to Advance Healthcare

Allison Gardner, PhD,
VP Educational Strategy and Content,
Med-IQ

Dr. Glenn Treisman,
Department of Psychiatry, Johns Hopkins Medical Institute

The Pros and Cons of Technology on the Practice of Medicine

Dr. Glenn Treisman,
Department of Psychiatry,
Johns Hopkins Medical Institute


Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.